GALNF: AI 评分 46/100 — AI 分析 (4月 2026)

Galenica AG is a Swiss healthcare provider operating through Products & Care and Logistics & IT segments. The company manages pharmacies, offers medication services, and provides specialized pre-wholesale services to pharmaceutical companies.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Galenica AG, a Swiss healthcare leader, operates pharmacies under brands like Amavita and Sun Store, alongside providing logistics and IT solutions to the pharmaceutical industry. With a focus on integrated healthcare services, Galenica leverages its distribution network and pharmacy operations to maintain a strong position in the Swiss healthcare market.

GALNF是做什么的？

Founded in 1927 and headquartered in Bern, Switzerland, Galenica AG has evolved into a prominent healthcare service provider. The company operates through two primary segments: Products & Care and Logistics & IT. The Products & Care segment manages a network of pharmacies and partner pharmacies under well-known brands such as Amavita, Sun Store, and Coop Vitality. This segment also includes mediservice, a specialty pharmacy, and offers medication for home treatment, laboratory medicine, pathology, and personalized diagnostic services. Galenica develops, markets, and sells healthcare services and products through various distribution channels, catering to a wide range of patient needs. The Logistics & IT segment provides specialized pre-wholesale services, including storage, distribution, and debt collection, to pharmaceutical and healthcare companies. It also develops management solutions for the healthcare market, publishes technical information on pharmaceutical products, and offers complete management solutions for pharmacies. Galenica's comprehensive service offerings and established market presence have solidified its position as a key player in the Swiss healthcare landscape.

GALNF的投资论点是什么？

Galenica AG presents a compelling investment case based on its integrated healthcare service model and strong market position in Switzerland. With a market capitalization of $6.17 billion and a healthy ROE of 12.1%, the company demonstrates financial stability. Growth catalysts include expansion of its pharmacy network and increased demand for its logistics and IT services. A potential risk factor is the competitive landscape in the Swiss healthcare market. The company's consistent profitability, indicated by a 4.4% profit margin, and its established infrastructure support a positive long-term outlook. The debt-to-equity ratio of 70.09% should be monitored for potential financial strain.

GALNF在哪个行业运营？

Galenica AG operates within the healthcare sector, specifically in medical distribution and pharmacy services. The Swiss healthcare market is characterized by high standards and a focus on quality. The company's integrated approach, combining pharmacy operations with logistics and IT services, positions it favorably in this competitive landscape. Market trends include increasing demand for personalized medicine and digital healthcare solutions. Galenica's established network and comprehensive service offerings enable it to capitalize on these trends and maintain a competitive edge.

Medical Distribution

Healthcare

GALNF有哪些增长机遇？

Expansion of Pharmacy Network: Galenica AG can grow by expanding its pharmacy network under the Amavita, Sun Store, and Coop Vitality brands. The Swiss pharmacy market is valued at several billion dollars annually. Strategic acquisitions and partnerships with independent pharmacies can accelerate this growth. The timeline for expansion is ongoing, with continuous efforts to increase market share and geographic reach. This expansion will allow Galenica to capture a larger share of the retail pharmacy market and enhance its brand presence.
Increased Demand for Logistics and IT Services: The Logistics & IT segment can benefit from the increasing demand for specialized pre-wholesale services in the pharmaceutical industry. This includes storage, distribution, and debt collection. The market for pharmaceutical logistics is growing due to the increasing complexity of supply chains and regulatory requirements. Galenica's expertise in this area provides a competitive advantage. The timeline for growth is immediate, with ongoing efforts to secure new contracts and expand service offerings.
Development of Digital Healthcare Solutions: Galenica AG can capitalize on the growing trend of digital healthcare by developing and offering innovative digital solutions. This includes telemedicine platforms, mobile health apps, and online pharmacy services. The market for digital healthcare is rapidly expanding, driven by increasing internet penetration and patient demand for convenient healthcare options. Galenica's existing infrastructure and customer base provide a strong foundation for this growth. The timeline for development is ongoing, with continuous investment in research and development.
Personalized Medicine and Diagnostic Services: The company can further expand its personalized medicine and diagnostic services, including laboratory medicine, pathology, and specialized personalized diagnostic services. The market for personalized medicine is growing due to advancements in genomics and precision medicine. Galenica's expertise in this area allows it to offer tailored treatment options and improve patient outcomes. The timeline for expansion is ongoing, with continuous efforts to develop new diagnostic tests and personalized treatment plans.
Strategic Partnerships and Acquisitions: Galenica AG can pursue strategic partnerships and acquisitions to expand its service offerings and geographic reach. This includes partnering with other healthcare providers, technology companies, and pharmaceutical manufacturers. Strategic acquisitions can provide access to new markets, technologies, and customer segments. The timeline for partnerships and acquisitions is ongoing, with continuous evaluation of potential opportunities. These partnerships and acquisitions will allow Galenica to enhance its competitive position and drive long-term growth.

Market capitalization of $6.17 billion reflects substantial investor confidence in Galenica AG's market position.
Profit margin of 4.4% indicates consistent profitability in the competitive healthcare sector.
Gross margin of 12.2% demonstrates the company's ability to manage costs effectively.
Return on Equity (ROE) of 12.1% signifies efficient utilization of shareholder equity to generate profits.
Debt-to-equity ratio of 70.09% suggests a moderate level of financial leverage.

GALNF提供哪些产品和服务？

Operates and manages pharmacies under the Amavita, Sun Store, and Coop Vitality brands.
Provides specialty pharmacy services through mediservice.
Offers medication for treatment of patients at home.
Provides laboratory medicine, pathology, and specialized personalized diagnostic services.
Develops, markets, and sells healthcare services and products through various distribution channels.
Provides specialized pre-wholesale services, including storage, distribution, and debt collection, to pharmaceutical and healthcare companies.
Develops management solutions for the healthcare market.
Publishes printed and electronic technical information on pharmaceutical products.

GALNF如何赚钱？

Revenue from pharmacy sales and services.
Income from logistics and IT services provided to pharmaceutical companies.
Sales of healthcare products through various distribution channels.
Fees from laboratory medicine, pathology, and diagnostic services.

Individual patients seeking pharmaceutical products and healthcare services.
Pharmaceutical companies requiring logistics and IT solutions.
Pharmacies and drugstores utilizing Galenica's management solutions.
Doctors, hospitals, and care homes receiving on-schedule delivery services.

Established brand recognition with well-known pharmacy brands like Amavita and Sun Store.
Integrated healthcare service model combining pharmacy operations with logistics and IT services.
Extensive distribution network providing efficient delivery services.
Specialized expertise in pre-wholesale services for the pharmaceutical industry.

什么因素可能推动GALNF股价上涨？

Upcoming: Expansion of pharmacy network through strategic acquisitions and partnerships.
Ongoing: Increasing demand for logistics and IT services from pharmaceutical companies.
Ongoing: Development and launch of new digital healthcare solutions.
Ongoing: Expansion of personalized medicine and diagnostic services.
Upcoming: Potential regulatory changes in the Swiss healthcare market.

GALNF的主要风险是什么？

Potential: Intense competition in the Swiss healthcare market.
Potential: Economic downturn affecting consumer spending on healthcare.
Ongoing: Changes in government regulations and reimbursement policies.
Potential: Emergence of new technologies disrupting the healthcare industry.
Ongoing: Limited liquidity due to trading on the OTC market.

GALNF的核心优势是什么？

Strong brand recognition in the Swiss healthcare market.
Integrated healthcare service model.
Extensive distribution network.
Specialized expertise in pre-wholesale services.

GALNF的劣势是什么？

Reliance on the Swiss market.
Exposure to regulatory changes in the healthcare industry.
Competition from larger pharmaceutical companies.
Potential for supply chain disruptions.

GALNF有哪些机遇？

Expansion into new geographic markets.
Development of digital healthcare solutions.
Strategic partnerships and acquisitions.
Increased demand for personalized medicine.

GALNF面临哪些威胁？

Intense competition in the healthcare sector.
Economic downturn affecting consumer spending on healthcare.
Changes in government regulations and reimbursement policies.
Emergence of new technologies disrupting the healthcare industry.

GALNF的竞争对手是谁？

Siegfried Holding AG — Focuses on pharmaceutical manufacturing and contract development. — (SIEHF)
Roche Holding AG — A global pharmaceutical and diagnostics company. — (ROHQF)
Novartis AG — A multinational pharmaceutical corporation. — (NOVN)

Key Metrics

MoonshotScore: 46/100

Company Profile

Headquarters: Bern, Switzerland
Employees: 4,727

AI Insight

AI analysis pending for GALNF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Galenica AG do?

Galenica AG is a leading healthcare service provider in Switzerland, operating through two main segments: Products & Care and Logistics & IT. The Products & Care segment manages pharmacies under brands like Amavita and Sun Store, offering pharmaceutical products and healthcare services directly to consumers. The Logistics & IT segment provides specialized pre-wholesale services, including storage, distribution, and IT solutions, to pharmaceutical companies. This integrated approach allows Galenica to serve as a comprehensive partner in the healthcare ecosystem, from manufacturing support to direct patient care.

What do analysts say about GALNF stock?

As of 2026-03-16, a comprehensive analyst consensus for GALNF is pending AI analysis. Key valuation metrics include a market capitalization of $6.17 billion, a profit margin of 4.4%, and a return on equity of 12.1%. Growth considerations revolve around the company's ability to expand its pharmacy network, capitalize on the increasing demand for logistics and IT services, and develop innovative digital healthcare solutions. Investors should monitor these factors to assess the stock's potential performance.

What are the main risks for GALNF?

Galenica AG faces several risks, including intense competition in the Swiss healthcare market, potential economic downturns affecting consumer spending on healthcare, and changes in government regulations and reimbursement policies. The emergence of new technologies could also disrupt the healthcare industry, requiring Galenica to adapt and innovate. Additionally, as the company trades on the OTC market, it faces risks associated with limited liquidity and less stringent reporting requirements compared to companies listed on major exchanges.